CR20250269A - Compuestos cíclicos fusionados y uso de los mismos - Google Patents
Compuestos cíclicos fusionados y uso de los mismosInfo
- Publication number
- CR20250269A CR20250269A CR20250269A CR20250269A CR20250269A CR 20250269 A CR20250269 A CR 20250269A CR 20250269 A CR20250269 A CR 20250269A CR 20250269 A CR20250269 A CR 20250269A CR 20250269 A CR20250269 A CR 20250269A
- Authority
- CR
- Costa Rica
- Prior art keywords
- cyclic compounds
- fused cyclic
- zrgdmfwvtptnr
- xgdo
- urrddjjaubih
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a compuestos cíclicos fusionados, una composición que contiene los mismos y el uso de los mismos. <img src="data:image/png;base64,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 (***)
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022137156 | 2022-12-07 | ||
| CN2023071719 | 2023-01-10 | ||
| CN2023084883 | 2023-03-29 | ||
| CN2023088433 | 2023-04-14 | ||
| CN2023101375 | 2023-06-20 | ||
| CN2023116529 | 2023-09-01 | ||
| CN2023119147 | 2023-09-15 | ||
| CN2023124703 | 2023-10-16 | ||
| CN2023129225 | 2023-11-02 | ||
| CN2023131834 | 2023-11-15 | ||
| CN2023135192 | 2023-11-29 | ||
| PCT/CN2023/136747 WO2024120433A1 (en) | 2022-12-07 | 2023-12-06 | Fused cyclic compounds and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20250269A true CR20250269A (es) | 2025-11-20 |
Family
ID=91378592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20250269A CR20250269A (es) | 2022-12-07 | 2023-12-06 | Compuestos cíclicos fusionados y uso de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4630429A1 (es) |
| JP (1) | JP2025540269A (es) |
| KR (1) | KR20250120376A (es) |
| CN (1) | CN120322440A (es) |
| AU (1) | AU2023388747A1 (es) |
| CL (1) | CL2025001678A1 (es) |
| CO (1) | CO2025009073A2 (es) |
| CR (1) | CR20250269A (es) |
| IL (1) | IL321332A (es) |
| MX (1) | MX2025006678A (es) |
| TW (1) | TW202440594A (es) |
| WO (1) | WO2024120433A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| CN114867726B (zh) | 2019-10-28 | 2023-11-28 | 默沙东有限责任公司 | Kras g12c突变体的小分子抑制剂 |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| CN120882725A (zh) * | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| WO2024230734A1 (en) * | 2023-05-08 | 2024-11-14 | Jacobio Pharmaceuticals Co., Ltd. | K-ras inhibitors and use thereof |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025085748A1 (en) | 2023-10-20 | 2025-04-24 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025146194A1 (en) * | 2024-01-05 | 2025-07-10 | Jacobio Pharmaceuticals Co., Ltd. | Fused tetracyclic compounds and use thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026021459A1 (zh) * | 2024-07-25 | 2026-01-29 | 上海和誉生物医药科技有限公司 | 一种具有kras抑制活性的化合物及其在药学上的应用 |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026061466A1 (en) * | 2024-09-20 | 2026-03-26 | Jacobio Pharmaceuticals Co., Ltd. | Fused tetracyclic compounds and use thereof |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| CA3210167A1 (en) * | 2021-02-09 | 2022-08-18 | Genentech, Inc. | Tetracyclic oxazepine compounds and uses thereof |
| WO2022188729A1 (en) * | 2021-03-07 | 2022-09-15 | Jacobio Pharmaceuticals Co., Ltd. | Fused ring derivatives useful as kras g12d inhibitors |
| EP4310091A4 (en) * | 2021-03-17 | 2025-04-16 | Genfleet Therapeutics (Shanghai) Inc. | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof |
| CN117083281A (zh) * | 2021-03-24 | 2023-11-17 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
| CN116113632B (zh) * | 2021-03-30 | 2025-08-29 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| CN117255793A (zh) * | 2021-06-21 | 2023-12-19 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
| KR20240029051A (ko) * | 2021-07-02 | 2024-03-05 | 상하이 드 노보 파마테크 컴퍼니 리미티드 | Kras g12d 억제제 및 이의 용도 |
| CN117677624A (zh) * | 2021-07-19 | 2024-03-08 | 上海艾力斯医药科技股份有限公司 | 新型吡啶并嘧啶衍生物 |
| WO2023001141A1 (en) * | 2021-07-23 | 2023-01-26 | Shanghai Zion Pharma Co. Limited | Kras g12d inhibitors and uses thereof |
| CN118019746A (zh) * | 2021-09-27 | 2024-05-10 | 北京加科思新药研发有限公司 | 多环稠环衍生物及其用途 |
-
2023
- 2023-12-06 KR KR1020257022688A patent/KR20250120376A/ko active Pending
- 2023-12-06 CR CR20250269A patent/CR20250269A/es unknown
- 2023-12-06 EP EP23900007.8A patent/EP4630429A1/en active Pending
- 2023-12-06 AU AU2023388747A patent/AU2023388747A1/en active Pending
- 2023-12-06 IL IL321332A patent/IL321332A/en unknown
- 2023-12-06 TW TW112147549A patent/TW202440594A/zh unknown
- 2023-12-06 WO PCT/CN2023/136747 patent/WO2024120433A1/en not_active Ceased
- 2023-12-06 CN CN202380083616.7A patent/CN120322440A/zh active Pending
- 2023-12-06 JP JP2025533157A patent/JP2025540269A/ja active Pending
-
2025
- 2025-06-06 MX MX2025006678A patent/MX2025006678A/es unknown
- 2025-06-06 CL CL2025001678A patent/CL2025001678A1/es unknown
- 2025-07-03 CO CONC2025/0009073A patent/CO2025009073A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024120433A1 (en) | 2024-06-13 |
| JP2025540269A (ja) | 2025-12-11 |
| KR20250120376A (ko) | 2025-08-08 |
| CN120322440A (zh) | 2025-07-15 |
| TW202440594A (zh) | 2024-10-16 |
| IL321332A (en) | 2025-08-01 |
| AU2023388747A1 (en) | 2025-07-10 |
| EP4630429A1 (en) | 2025-10-15 |
| CO2025009073A2 (es) | 2025-07-28 |
| MX2025006678A (es) | 2025-08-01 |
| CL2025001678A1 (es) | 2025-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20250269A (es) | Compuestos cíclicos fusionados y uso de los mismos | |
| CY1119100T1 (el) | Διαμορφωτες μεταφορεων κασετας συνδεσης με ατρ | |
| AR033472A1 (es) | Concentrados de agentes anticongelantes que contienen el colorante c.i. reactive violet 5 | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| ES2531009T3 (es) | Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos | |
| BR112012018496A2 (pt) | aparelho de marcação de substrato de marcação de um substrato usando o mesmo, e, de calibração de um aparelho de marcação de substrato | |
| CR20220252A (es) | Nuevos inhibidores de braf como rompedores de la paradoja | |
| AR104174A1 (es) | Oxadiazoles sustituidos con deuterio | |
| BRPI0417684A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| PA8623601A1 (es) | Protector para punta de aguja | |
| CU24743B1 (es) | Composiciones inmunogénicas contra el coronavirus | |
| GT200900187A (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso los mismos | |
| ES2530624T3 (es) | Composiciones de adhesivo | |
| BR112013027506A2 (pt) | bicicleta luminescente | |
| PY1965502A (es) | Activadores de la vía inducible del gen "rig-i" del ácido retinoico y métodos de uso de los mismos | |
| BRPI0815455B8 (pt) | compostos derivados de n-fenilacetamida, composição farmacêutica, composição cosmética, uso cosmético de uma composição, e usos de um composto do mesmo | |
| CU24719B1 (es) | Derivados de hidroquinona disustituidos en 2,5 o 2,6 con un grupo carboxi, sulfo o amido útiles como medicamentos | |
| ECSP066912A (es) | Formulaciones de dispersiones sólidas de acetato de bazedoxifeno | |
| BR102015010568B8 (pt) | Composições de filtro solar contendo um poliglicerol capaz de absorver luz uv e um poliglicerol não capaz de absorver luz uv | |
| MX2019006142A (es) | Composiciones para el cuidado bucal y metodos de uso. | |
| RU2008151416A (ru) | Производные 1-алкенилимидазола | |
| BRPI0418372A (pt) | proteìnas e genes de complexo de toxina de xenorhabdus bovienii | |
| AR107310A1 (es) | Inhibidores de tetrahidrocarbazol de receptores sirt1 | |
| SE0101220D0 (sv) | New use | |
| PY1965505A (es) | Activadores de la vía inducible del gen "rig-i" del ácido retinoico y métodos de uso de los mismos |